NCT01327521

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Albert Koong · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Primary Objective: To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE. Secondary Objectives: 1. To determine the progression-free survival of TACE vs. CyberKnife SBRT 2. To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC 3. To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of recurrent HCC.

Conditions

• Carcinoma, Hepatocellular

Interventions

Type	Name	Description
DEVICE	CyberKnife	Standard of Care
PROCEDURE	TACE	Standard of Care
DRUG	CT Contrast	Standard of Care
DRUG	doxorubicin	Standard of Care
DRUG	Epirubicin	Standard of Care
DRUG	5-fluorouracil	Standard of Care
DRUG	Mitomycin C	Standard of Care
DRUG	Gemcitabine	Standard of Care
DRUG	Cisplatin	Standard of Care
DEVICE	SMANCS	Standard of Care

Timeline

• Start date: 2011-02-01
• Primary completion: 2014-02-01
• First posted: 2011-04-01
• Last updated: 2012-06-11

Locations

1 site across 1 country: United States